NPM1 and acute myeloid leukemia: SORMAIN was a phase 2 randomized placebo-controlled double-blind maintenance trial comparing single-agent sorafenib to placebo in patients with FLT3mut AML (with or without NPM1 mutation) who were in complete hematologic remission after undergoing allo-SCT.